Seeking the solution to the problem of metastatic renal carcinoma

Cancer

Volumn 97, Issue 12, 2003, Pages 2941-2944

  Russo, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNITED STATES;

HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 0038348649     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11439     Document Type: Review

References (23)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics 2003. CA Cancer J Clin. 2003;53:5-43.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
3. Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol. 2000;27:160-176.
4. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
5. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2859-2867.
6. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7:135-140.
7. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
8. Kavolius JP, Mastorakos DP, Pavolvich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261-2266.
9. Pantuck A, Zismon A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer. 2003;97:2995-3002.
10. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68-72.
11. Kovacs G, Akhtar M, Beckwith B, et al. The Heidelberg classification of renal cell tumors. J Pathol. 1997;183:131-133.
12. Illiopolulos O, Eng C. Genetic and clinical aspects of familial renal neoplasms. Semin Oncol. 2000;27:138-149.
13. Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM. Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol. 1999;162:1246-1258.
14. Zbar B, Glenn G, Lubensky I, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol. 1995; 153:907-912.
15. Weirich G, Glenn G, Junker K, et al. Familial renal oncocytoma: clinicopathological study of 5 families. J Urol. 1998; 160:335-340.
16. Torro JR, Glenn G, Duray P, et al. Birt Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol. 1999; 135:1195-1202.
17. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 2000;73:730-736.
18. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol. 2002;20:2376-2381.
19. Taipale J, Makinen T, Arighi E, et al. Vascular endothelial growth factor receptor -3. Curr Top Microbiol Immunol. 1999;237:85-96.
20. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186-191.
21. Gunningham SP, Currie MJ, Han C, et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res. 2001;61:3206-3211.
22. Gordon MS, Margolin K, Talpaz M, et al. Phase 1 safety and pharmacologic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-850.
23. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)lleucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21: 60-65.